Leflunomide Zentiva

Leflunomide, the active ingredient in Leflunomide Zentiva, is an immunomodulatory DMARD presented as a tablet for oral use. It is used to treat rheumatoid arthritis and psoriatic arthritis in adult patients. GNH USA supplies Leflunomide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease‑modifying antirheumatic drug that targets inflammatory joint disorders. - Rheumatoid arthritis: reduces joint inflammation, pain and structural damage. - Psoriatic arthritis: improves skin lesions and joint symptoms. - Adults with active disease when other DMARDs are insufficient: provides an alternative disease‑modifying option.

Leflunomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhoea: loose stools occurring during early treatment. - Nausea: occasional upset stomach or feeling of queasiness. - Alopecia: reversible hair thinning or loss. - Rash: mild skin eruptions or itching. - Elevated liver enzymes: mild increases in ALT/AST. - Hypertension: modest rise in blood pressure.

Serious or Rare Side Effects: - Severe liver injury: jaundice, fatigue, dark urine. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Bone‑marrow suppression: low blood counts, increased infection risk. - Interstitial lung disease: persistent cough, shortness of breath. - Severe infections: opportunistic bacterial or viral illnesses. - Teratogenicity: potential birth defects if exposure occurs during pregnancy.

Before initiating Leflunomide, clinicians should assess baseline health and monitor ongoing safety. - Liver function monitoring: check ALT/AST before start and periodically thereafter. - Blood pressure control: measure regularly, especially in hypertensive patients. - Pregnancy avoidance: do not use in women who are pregnant or may become pregnant. - Infection vigilance: postpone therapy in active severe infections. - Renal impairment caution: adjust use in patients with significant kidney dysfunction. - Store below 25°C: keep in the original pack, protect from moisture.

Leflunomide interacts with several medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Statins: heightened risk of liver toxicity. - Live vaccines: possible severe infection due to immunosuppression. - Carbamazepine: reduces Leflunomide plasma levels, lowering efficacy. - Azathioprine: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - NSAIDs: may raise liver enzyme levels. - Methotrexate: combined hepatotoxic potential. - Antihypertensives: possible reduction in blood‑pressure control. - Oral contraceptives: decreased hormonal efficacy. - Allopurinol: increased risk of rash and hypersensitivity.